Publications by authors named "Kristi Mclendon"

Claim this Profile
A
A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults.
Rupert Davies, Stanford L Peng, Jason Lickliter, Kristi McLendon, Amanda Enstrom

Clin Transl Sci· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects.
Yue Fei, Na Li, Weilin Qian, Yang Fan, Yu Shen, Kristi McLendon

Front Pharmacol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Profiles of a Proposed Biosimilar Ustekinumab (BFI-751): Results From a Randomized Phase 1 Trial.
Jeffrey N Hausfeld, Rodeina Challand, Kristi McLendon, Nathaniel Macapagal, Pam Bruce-Staskal

Clin Pharmacol Drug Dev· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults.
Christopher Wynne, Paul Hamilton, Kristi McLendon, Heimo Stroissnig, Matthew Smith

Expert Opin Investig Drugs· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: A randomised, double-blind, parallel-group, Phase 1 trial.
Marcus Maurer, Sarbjit S Saini, Kristi McLendon, Paul Wabnitz, Sunghyun Kim

Clin Transl Allergy· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin and US-Herceptin in healthy male subjects.
Martin Demarchi, Pierre Coliat, Kristi Mclendon, Jocelyn Chung Shii Hii, Peggy Feyaerts

Pharmacol Res Perspect· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis